Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.

An AbbVie schizophrenia drug acquired as part of a ... significantly lower than what was reported for Cobenfy’s Phase 3 test. The AbbVie drug’s studies also had higher placebo responses ...

Researchers have identified a potential diagnostic tool for schizophrenia by measuring brain cell activity between the ...

Researchers have developed a potential diagnostic tool for schizophrenia by observing how patients process conflicting information.

In contrast, a person with schizophrenia may be unable to consider the evidence ... Informed by the animal data, the research ...

For patients with schizophrenia, repetitive transcranial magnetic stimulation (rTMS) was effective and safe in treating ...

The FDA started the blood tests to watch for the risk of severe ... Littlefield, who has schizophrenia and bipolar disorder, wants to learn more about the experiences of people who've taken ...

and the Cochran’s Q test showed significant heterogeneity for Betaproteobacteria (P =.010; I² = 55.3%). The researchers concluded, “The findings may provide evidence for the treatment of gut ...